CEL SCI CORP (CVM)

NYSE Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$1.9M
Cash & Equivalents
$8.0M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$24M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT02991690 Systemic Hypothermia in Acute Cervical Spinal Cord Injury OTHER Recruiting 120

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-06-16 8-K CEL SCI CORP (CVM) (CIK 0000725363) - PLACEMENT AGENCY AGREEMENT EDGAR

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CVM.

SEC EDGAR Filings

All SEC filings for CEL SCI CORP on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.